Valuation
- Market cap
- 236,579,000
- Revenue TTM
- $3,500,000
- Net income TTM
- $-80,400,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -2,297.14%
- Debt to equity
- 0.00
Trading
- Volume
- 72,100
- Avg volume
- 302,764
- Day's range
- $3.62 – $3.87
- Shares out
- 62,753,000
- Stochastic %K
- 41%
- Beta
- 0.27
- Analysts
- Strong Sell
- Price target
- $10.12
Company profile
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Mara...
Show more
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 617 651 8867
- Website
- https://www.camp4tx.com
- Address
- One Kendall Square, 3rd Floor Building 1400 West, Cambridge, United States
Latest news
No headlines yet.
